VJHemOnc is committed to improving our service to you

iwCLL 2019 | Predicting TLS in venetoclax-treated CLL patients

VJHemOnc is committed to improving our service to you

Anthony Mato

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, talks about predicting tumor lysis syndrome (TLS) in venetoclax-treated chronic lymphocytic leukemia (CLL) patients. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter